Gastrointestinal malignancies represent a common and heterogeneous group of tumors and account for a high percentage of adult cancers. Over the past decades, early detection, advanced endoscopy and surgery, along with the additional benefit in some cases from perioperative treatment, have led to improved outcomes in localized disease.
Editorial
Immunotherapy for gastrointestinal malignancies: the journey does not end here!
Review Article
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Colon cancer and immunotherapy—can we go beyond microsatellite instability?
Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?
Editorial
Pancreatic cancer and immune checkpoint inhibitors—still a long way to go
Review Article
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms
Editorial
Anal cancer and immunotherapy—are we there yet?
Review Article
Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?
Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?
Finding the hot spot: identifying immune sensitive gastrointestinal tumors
Disclosure:
The series “GI Malignancies and Immunotherapy” was commissioned by the editorial office, Translational Gastroenterology and Hepatology without any sponsorship or funding. Khaldoun Almhanna served as the unpaid Guest Editor for the series.
The series “GI Malignancies and Immunotherapy” was commissioned by the editorial office, Translational Gastroenterology and Hepatology without any sponsorship or funding. Khaldoun Almhanna served as the unpaid Guest Editor for the series.